NHL Alumni Association teams up with Canopy Growth to research concussions and cannabinoids New study led by NEEKA Health Canada will test if CBD-based therapies can reduce the severity of post-concussion brain disorders

NHL Alumni Association teams up with Canopy

Growth to research concussions and cannabinoids

New study led by NEEKA Health Canada will

test if CBD-based therapies can reduce the severity of post-concussion brain disorders in former NHL players

TORONTO and SMITHS FALLS, ON, March 2, 2019

/CNW/ - NHL Alumni Association (NHLAA), NEEKA Health Canada and Canopy Growth Corporation ("Canopy Growth" or the

"Company") (TSX: WEED) (NYSE: CGC) are pleased to announce a transformative clinical research partnership that will investigate

the efficacy of cannabinoids as an integral part of a novel treatment for post-concussion neurological diseases in former NHL players.

New study led by NEEKA Health Canada will test

if CBD-based therapies can reduce the severity of post-concussion brain disorders in former NHL players (CNW Group/Canopy Growth

A substantial number of these high performing,

former professional athletes have developed impairments as a result of past concussions, ranging from depression, post-traumatic

stress disorders (PTSD) and progressive dementia from chronic traumatic encephalopathy (CTE). In some cases, this leads to debilitating

limitations in their ability to cope with their environment, a term NEEKA Health Canada has defined as functional disintegration.

This study will undertake the rigorous science needed to establish the medicinal value of cannabis when combined with other proven

treatments amongst this highly-afflicted group of elite athletes and potentially improve their ability to interact with family,

friends and their communities.

Researchers estimate that between 1.6 and 3.8

million athletes suffer from a sports-related concussion each year*. Ten to 15 percent of these athletes will go on to develop

chronic post-concussion symptoms that can affect their ability to function. The results of this original study may also lead to

new cannabinoid-based therapies that help athletes in other professional sports, along with adults who suffer from the aftermath

of brain injuries from accidents and other activities.

"NHL alumni gave everything they had during

their careers, but the physical consequences after they hang up their skates can be devastating for both players and their loved

ones for the rest of their lives," said Glenn Healy, Executive Director of the NHLAA. "This study offers alumni the promise

of help and hope, and we are excited to participate in what could become a true game-changer in allowing these professional athletes

Approximately 100 former players will be enrolled

in this randomized double-blind study. The research will be led by NEEKA Health Canada's Dr. Amin Kassam, a world-renowned neurosurgeon

who completed his undergraduate training at the University of Toronto and has led four neurosurgery programs over two decades.

Joining Dr. Kassam is Dr. Richard Rovin, a neurosurgeon who completed post-graduate training through the Global Clinical Scholars

Research Training Program at Harvard University Medical School. Their combined expertise in neuroscience, molecular cell signaling,

brain mapping, and clinical trial design may lead to novel cannabis therapies that have the potential to improve the lives of patients

suffering from post-concussion healthcare issues.

"We have seen the debilitating effects

of chronic repeated head injuries on the lives of patients and their families," said Dr. Amin Kassam, Founder and CEO of NEEKA

Health Canada. "Our team is excited to partner with Canopy Growth, a global leader in cannabis science and the NHL Alumni

Association, a committed organization to its players, to demonstrate the immense and unexplored opportunity in cannabis-based remedies,

particularly when synergized by novel treatment paradigms such as digital mental health and behavioral therapy."

"This complex and multidimensional study

will give us an unprecedented understanding of the interaction between cannabidiol (CBD) and the brains and behaviours of former

NHL players living with post-concussion symptoms," said Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We thank

the members of the NHLAA whose willingness to join this unique research partnership speaks to the need for alternative medical

treatments to treat the long-term and often devastating effects of concussions."

The study is expected to begin in summer 2019

and will take one year to complete. The results of this unprecedented trial could also catalyze new research initiatives further

investigating the potential of CBD as a treatment to help people recover from their brain injuries.

Here's to Future Growth (and goals).

The NHL Alumni Association (NHLAA), established in 1999, is a charitable organization in Canada and the US that serves as a passionate

advocate devoted to bettering the lives of its members (all former NHL Players). The NHLAA exemplifies this commitment to its members

in many different ways including financial assistance, commercializing players' rights, emotional support, physical care, post

playing career transition and family aid all in furtherance of its efforts to 'Honour the Past'. Since its inception, the NHLAA

has acted as a liaison with its 29 local chapters and has become the largest membership association for retired professional hockey

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties

in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company's subsidiary, Storz

& Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for

leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has

operations in over a dozen countries across five continents.

The Company is proudly dedicated to educating

healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through

its wholly owned subsidiary, Canopy Health Innovations ("Canopy Health"), has devoted millions of dollars toward cutting

edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy

Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property

protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. ("ebbu"). Intellectual Property

("IP") and R&D advancements achieved by ebbu's team apply directly to Canopy Growth's hemp and THC-rich cannabis

genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation,

the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the

From our historic public listing on the Toronto

Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through

leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including

cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world's largest nonprofit research

and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten

licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet

of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply

agreements with every Canadian province and territory. For more information visit www.canopygrowth.com

NEEKA Enterprises founded by neurosurgeon Dr. Amin Kassam, is a health care entity that provides broad ranging services, including,

econometric modeling and strategic health care transformation. The Canadian clinical subsidiary of NEEKA Enterprises, NEEKA Health

Canada, will co-ordinate the unprecedented National Hockey League Alumni Association trial from its headquarters in Charlottetown,

Prince Edward Island, Canada. Built on the scientific underpinning of Dr. Amin Kassam and Dr. Richard Rovin, NEEKA Health Canada

will bring its competencies in the fields of economic modeling, machine learning, bioinformatics and patient empowerment to transform

the lives of those suffering from post-concussion healthcare issues.

Notice Regarding Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation

Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation.

Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans",

"expects" or "does not expect", "is expected", "estimates", "intends", "anticipates"

or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions,

events or results "may", "could", "would", "might" or "will" be taken, occur

or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which

may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from

any future results, performance or achievements expressed or implied by the forward-looking statements or information contained

in this news release. Examples of such statements include statements with respect to "transformative clinical research partnership",

and "results of this original study may also lead to new cannabinoid-based therapies". Risks, uncertainties and other

factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities

to differ materially from those expressed or implied by such forward-looking information, including research outcomes, timeline

for publishing results, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian

securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the

assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are